Systemic hemostatic medications for reducing surgical blood loss

Area of Science:

• Anesthesiology and Perioperative Medicine
• Pharmacology
• Surgical Hemostasis

Background:

• Systemic hemostatic medications are used to control surgical bleeding.
• Evidence for their efficacy in reducing blood loss and transfusion requirements is variable.

Purpose of the Study:

• To review randomized trials on systemic hemostatic medications for reducing surgical blood loss.
• To evaluate the efficacy and evidence base for common hemostatic agents.

Main Methods:

• Systematic review of randomized trials and pharmacoeconomic evaluations.
• Searched MEDLINE and reviewed bibliographies for relevant studies (1966-September 2000).
• Extracted data on conjugated estrogens, aminocaproic acid, tranexamic acid, desmopressin, and aprotinin; excluded specific bleeding types and cardiovascular surgery agents.

Main Results:

• Conjugated estrogens have limited efficacy and toxicity data.
• Aminocaproic acid and tranexamic acid have limited studies with conflicting or negative results, except tranexamic acid for knee surgery.
• Desmopressin shows lack of efficacy in numerous trials.
• Aprotinin shows promise in orthopedic surgery but requires cost-effectiveness analysis; hepatic surgery results are conflicting.

Conclusions:

• Most systemic hemostatic medications have limited or contradictory evidence of efficacy for reducing surgery-related bleeding.
• Further research, including cost-effectiveness studies, is needed for agents like aprotinin.
• The therapeutic role of many hemostatic agents remains uncertain.